• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Chagas Access Programme achieves an increase of 1300% in the number of people screened

Home > Press releases

Chagas Access Programme achieves an increase of 1300% in the number of people screened

Chagas patient receives check-up at the hospital
Yopal, Colombia — 20 Jun 2019

The Drugs for Neglected Diseases initiative (DNDi) and the Casanare Departmental Health Secretariat have announced the successful results of a programme for the elimination of barriers to the diagnosis and treatment of Chagas disease in several municipalities in Colombia. The programme, which was launched two years ago, led to an increase of 1300% in the number of people screened in Támara and Nunchía. For those who had access to diagnostic testing, the wait time to receive their results was reduced from one year to less than one month, on average. Approximately 20% of people who had access to diagnosis during the two-year period tested positive for the disease.

“There are many barriers to access to diagnosis and treatment of Chagas disease. However, the numbers show that it is possible to improve access and promote important changes in health care with simple measures and current resources,” said Dr Andrea Marchiol, Medical Manager of DNDi‘s Chagas access projects for Latin America.

The improved access is the result of close collaboration between DNDi, the Ministry of Health and Social Protection, the National Health Institute, the Orinoquía Regional Hospital (HORO), and the Departmental Health Secretariat.

After identifying the main barriers hindering access to diagnosis and treatment of Chagas in Colombia, an integral health care path was designed, focusing on people living with the disease. This simplified the process by transferring diagnosis and treatment to primary care centres, which are closer to communities. For this change to be effective, local capacities in the health care system and the community were strengthened. The project was implemented in the municipalities of the Boyacá, Santander, and Arauca departments, as well as in Nunchía and Támara, in collaboration with the respective health secretariats.

According to data from the World Health Organization (WHO), Chagas disease affects more than 6 million people globally, particularly in Latin America. Without timely treatment, this silent disease can affect vital organs such as the heart, causing severe damage to health. Chagas is transmitted through contact with the contaminated feces of the insect known as the “kissing bug”. This typically occurs after this vector bites a person. Chagas can also be transmitted by an infected pregnant woman to her baby, by eating contaminated foods, or through blood transfusion or organ transplant. In Colombia, it is estimated that 4.8 million people are at risk of contracting the disease, 436,000 are infected, and 130,000 have some type of heart damage as a consequence of the disease. However, it is estimated that only 1.2% of the population at risk has been screened, and only 0.4% of those have received treatment against the parasite.

Another significant change brought by the programme is that younger people have better access to diagnosis. This is important because the sooner the disease is detected, the more effective the treatment can be.

“The requisition of diagnostic tests was based only on the symptoms. Now the doctor’s perspective has started to change, and they think about Chagas not only in terms of its symptoms, but also in terms of the risks. Since Chagas is a silent disease, if we only look for symptoms, we fail to identify many affected people,” said Dr Rafael Herazo, Chagas access project medical consultant.

“After two years, we are no longer talking about a pilot. Now we have an institutionally consolidated process with positive impact on the health of the populations affected by Chagas disease. Our task now is to scale the implementation of the healthcare path at the departmental level,” added Dr Fernando Torres, Head of the Programme for vector-transmitted diseases in the Casanare department

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, in particular those suffering with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, pediatric HIV, and hepatitis C. Since its inception in 2003, DNDi has delivered eight new treatments. DNDi’s strategy for Chagas disease consists of three pillars: improving diagnostic and therapeutic tools through innovation in research & development, fostering collaboration and strengthen capacity in endemic countries through a scientific platform, and increasing patients’ access to diagnosis and treatment.

Media contact

Alessandra Vilas Boas
avilasboas@dndi.org
+44 7484661366

Photo credit: Felipe Abondano – DNDi

Registration & access Chagas disease

Read, watch, share

Loading...
News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

News
5 Jun 2025

Meet the DNDi Eastern Africa 2024-2025 Media Fellows

Press releases
5 Jun 2025

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License